Repligen Corporation to Present at Upcoming May Investor Conferences

Rhea-AI Summary

Repligen (NASDAQ:RGEN) will attend several investor conferences in May, including RBC Capital Markets' Global Healthcare Conference in New York, Craig-Hallum's Institutional Investor Conference in Minneapolis, and Leerink Partners' Healthcare Crossroads Conference in Austin. Jason K. Garland, Chief Financial Officer, will participate in analyst-led discussions and one-on-one meetings with investors at each event. Live webcasts of the RBC and Leerink presentations will be accessible via Repligen's Investor Relations website.

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

• RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings with investors.
• Craig-Hallum’s 21^st Annual Institutional Investor Conference, being held in Minneapolis on May 29. Jason K. Garland, Chief Financial officer will participate in a series of one-on-one meetings with investors.
• Leerink Partners’ 2024 Healthcare Crossroads Conference, being held in Austin, Texas on May 28-29. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 30, 2024 at 8:40 a.m. CT, in addition to a series of one-on-one meetings with investors.

A live webcast of the RBC and Leerink conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

FAQ

What investor conferences is Repligen participating in May 2024?

Repligen is participating in RBC Capital Markets' Global Healthcare Conference, Craig-Hallum's Institutional Investor Conference, and Leerink Partners' Healthcare Crossroads Conference in May 2024.

Who will represent Repligen at the conferences?

Jason K. Garland, Chief Financial Officer, will represent Repligen at the investor conferences in May 2024.

Where can I access the webcasts of the RBC and Leerink conference presentations?

The webcasts of the RBC and Leerink conference presentations will be accessible through Repligen's Investor Relations website at www.repligen.com.